Eli Lilly Grants Compassionate Use of Obesity Drug to 79-Year-Old Patient, Sparking Speculation
A 79-year-old patient received special access to Eli Lilly’s experimental obesity drug, retatrutide, under the company’s compassionate use program, according to a report by StatNews. The case has raised questions about the criteria for such approvals and fueled speculation about the patient’s identity, with some outlets suggesting former President Donald Trump could be the individual. However, Eli Lilly has not confirmed the patient’s identity, and no official statement has been released.
What is Retatrutide?
Retatrutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of obesity. It works by mimicking hormones that regulate appetite and glucose metabolism. The drug is currently under review by the U.S. Food and Drug Administration (FDA) but has not yet received full approval. Compassionate use programs allow patients with serious or life-threatening conditions to access investigational drugs outside of clinical trials when no other treatments are available.
Compassionate Use Criteria and Regulatory Oversight
The FDA’s compassionate use program requires that patients meet strict criteria, including a diagnosis of a serious condition and no viable alternative treatments. According to a statement from the FDA, “Compassionate use is intended for patients with serious or immediately life-threatening diseases or conditions who have no other options and are unable to participate in a clinical trial.” However, the process is typically reserved for rare or severe cases, making the approval for a 79-year-old patient with obesity noteworthy.
Speculation About the Patient’s Identity
Speculation about the patient’s identity emerged after Mother Jones reported that the case was “odd” given the patient’s age and the drug’s experimental status. The outlet noted that retatrutide had not yet been approved for general use, and its safety profile was still being evaluated. While no official confirmation has been provided, some analysts suggested that the case could reflect broader debates about access to experimental therapies for high-profile individuals. A spokesperson for Eli Lilly declined to comment on the patient’s identity, stating, “We do not disclose details about compassionate use cases.”
What Happens Next?
The situation highlights the growing demand for obesity treatments amid a public health crisis. The Centers for Disease Control and Prevention (CDC) reports that over 42% of U.S. adults are obese, and new therapies like retatrutide could play a critical role in addressing the issue. However, the use of experimental drugs outside clinical trials remains controversial. The FDA has emphasized that compassionate use should not undermine the integrity of drug development processes, but advocates argue that it provides vital options for patients in urgent need.
As the story unfolds, stakeholders will be watching for updates from Eli Lilly and the FDA. The case also underscores the ethical and regulatory challenges of balancing innovation with patient safety in the rapidly evolving field of obesity treatment.